BRIEF—LifeArc adds to research fund for infectious diseases

In the UK, the Liverpool School of Tropical Medicine (LSTM) has partnered with the LifeArc medical research group to establish a $3.4 million Translational Development Fund.

The new fund will form part of the Infection Innovation Consortium (iiCON), a program with around $320 million in funding led by the LSTM with multiple other partners.

The goal of the program is to bring together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and innovations.

LifeArc will also make its antibody humanization platform available to iiCON and its collaborators. The new money will be focused on medicines for people in low and middle-income countries.

LifeArc global health head Mike Strange said the group was “committed to investing over $125 million in global health, with a focus on infectious diseases, over the coming years.”